In the third part of WIPR’s forecast series, leading lawyers offer their views on, what lies ahead for artificial intelligence in the IP landscape, and the beleaguered Patent Trial and Appeal Board’s (PTAB) likely future stance on the NHK-Fintiv rule and Arthrex-related requests for inter partes reviews of patents.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
22 March 2022 The US Supreme Court has rejected an attempt by Intel to challenge the controversial NHK- Fintiv rule, the latest in a series of denials meted out to tech companies and generic drug makers seeking the same review.
25 April 2022 The US Patent and Trademark Office is seeking input to help formalise the process that allows the director to review decisions handed down by the Patent Trial and Appeal Board.